Evidence-Based Case Report: Comparison of Potassium Competitive Acid Blocker and Proton Pump Inhibitor as First Line Therapy in Adult Patients with H. pylori Infection

Authors

  • Dewi Mustikarani Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
  • Henrico Citrawijaya Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta
  • Saskia Aziza Nursyirwan Division of Gastroenterology, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, Faculty of Medicine, Universitas Indonesia/Dr. Cipto Mangunkusumo General National Hospital, Jakarta

DOI:

https://doi.org/10.24871/2522024%25p

Abstract

ABSTRACT

Background: Increased eradication of Helicobacter pylori decreases the incidence of gastric cancer. Vonoprazan is a potassium-competitive acid blocker (PCAB) with a stronger acid production suppression effect than proton pump inhibitors (PPI). Vonoprazan has been recognized as a therapy for gastric acid reflux disease since 2015 in Japan, but the comparison of the effectiveness of PCAB first-line therapy with PPI for adult patients with H. pylori infection is still controversial.

Method: A literature search was carried out on three databases: Pubmed, Cochrane, and Scopus on March 30th 2023, using keywords vonoprazan, potassium competitive acid blocker (PCAB), proton pump inhibitor, and H. pylori. There were 7 studies on Pubmed, 26 studies on Cochrane, and 144 studies on Scopus. Critical screening was conducted using the Oxford Centre for Evidence-Based Medicine for systematic reviews and randomized controlled trials. Results: Based on screening of inclusion and exclusion criteria, one study met the criteria. The intention to treat analysis (ITT) showed eradication of H. pylori in the combination of three therapies with PCAB vs PPI of 91.81% vs 75.5% (1,18 [1.08−1.28], p<0,0001), no heterogeneity found (I2 = 43%). Analysis per protocol showed PCAB versus PPI eradications of 92.99% vs 78.57% (1,13 [1,02−1,26], p = 0.02), heterogeneity obtained (I 2 = 75%). 

Conclusion: Generally, PCAB has better eradication than PPI as first-line therapy for adult patients with H. pylori infection 

Keywords: potassium competitive acid blocker, proton pump inhibitors, helicobacter pylori

Downloads

Published

2024-07-23

How to Cite

Mustikarani, D., Citrawijaya, H., & Nursyirwan, S. A. (2024). Evidence-Based Case Report: Comparison of Potassium Competitive Acid Blocker and Proton Pump Inhibitor as First Line Therapy in Adult Patients with H. pylori Infection. The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy, 25(2), 170–175. https://doi.org/10.24871/2522024%p

Issue

Vol. 25 No. 2 (2024): VOLUME 25, NUMBER 2, August, 2024

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

a. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

b. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

c. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).